The relevant information included in this section is exactly as published on the website of the National Securities Market Commission (CNMV).
Filter results:
Year
v
SEARCH
| Date | Title | |
|---|---|---|
| 21/04/2017 | 2017 first quarter results press release | |
| 21/04/2017 | 2017 first quarter results presentation | |
| 13/03/2017 | The biosimilar of Enoxaparin, a great opportunity for ROVI | |
| 13/03/2017 | Presentation related to ROVI Enoxaparin biosimilar | |
| 10/03/2017 | The Decentralised procedure used for the registration of ROVI's biosimilar of enoxaparin has been completed with positive outcome. | |
| 07/03/2017 | The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome. | |
| 16/02/2017 | Full Year 2016 results press release | |
| 16/02/2017 | Full year 2016 results presentation | |
| 09/02/2017 | Incorporation of two doctors to the R&D&I within the "Torres Quevedo" program |